Beijing Strong Biotechnologies, Inc. of Beijing at MEDICA 2017 in Düsseldorf -- COMPAMED Trade Fair

Beijing Strong Biotechnologies, Inc.

No.15, Norh Second Street Yanqi Economic, Development Area, Huairou District, 100043 Beijing
China, People’s Republic

Telephone +86 10 61667168
Fax +86 10 61667810
gww@bsbe.com.cn

Hall map

MEDICA 2017 hall map (Hall 18): stand G23

Fairground map

MEDICA 2017 fairground map: Hall 18

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.11  Controls / Standards / Calibrators clinical chemistry

Controls / Standards / Calibrators clinical chemistry

Our products

Product category: Controls / Standards / Calibrators clinical chemistry

ADA

INTENDED USE

Adenosine deaminase (ADA) assay kit is for determination of ADA activity in human serum samples. ADA is an enzyme catalyzing the deamination reaction from adenosine to inosine. The enzyme is widely distributed in human tissues, especially high in Tlymphocytes. Elevated serum ADA activity has been observed in patients with acute hepatitis, alcoholic hepatic fibrosis, chronic active hepatitis, liver cirrhosis, viral hepatitis and hepatoma. Increased ADA activity was also observed in patients with tuberculous effusions. Determination of ADA activity in patient serum may add unique values to the diagnosis of liver diseases in combination with ALT or γ-GT (GGT) tests. ADA assay may also be useful in the diagnostics of tuberculous pleuritis. 

PRINCIPLE
The ADA assay is based on the enzymatic deamination of adenosine to inosine which is converted to hypoxanthine by purine nucleoside phosphorylase (PNP). Hypoxanthine is then converted to uric acid and hydrogen peroxide (H2O2) by xanthine oxidase (XOD). H2O2 is further reacted with TOOS and 4-aminoantipyrine (4-AA) in the presence of peroxidase (POD) to generate quinone dye which is monitored in a kinetic manner. 

LINEARITY
The assay is linear up to ADA concentration of 200U/L. Sample above this concentration should be diluted 1+1 with 0.9% NaCl and reassay. Multiply the result by 2. 

INTERFERENCE
The following analytes were tested up to the levels indicated and found not to interfere:
Hemoglobin: up to 800 mg/dl
Intralipid: up to 1000 mg/dl
Ascorbic acid: up to 50 mg/dl

SENSITIVITY

The minimum detectable concentration of ADA with an acceptable level of precision was determined as 1 U/L.

PRECISION
The CV of the test should be less than 5%.

More Less

Product category: Controls / Standards / Calibrators clinical chemistry

Potassium

Method: Enzymatic Colorimetric

INTENDED USE
For the in vitro quantitative determination of potassium in serum and plasma. 

ASSAY PRINCIPLE
Potassium is determined enzymatically via potassium-dependant pyruvate kinase activity using phosphoenolpyruvate as substrate. The pyruvate formed reacts with NADH in the presence of LDH to form Lactate and NAD. The corresponding decrease in absorbance at 340nm is proportional to the potassium concentration.

LINEARITY
This method is linear between potassium concentrations of 2 and 10 mmol/L.

INTERFERENCE
The following analytes were tested up to the levels indicated and found not to interfere:
Introlipid≤1000mg/dl, Bilirubin≤30mg/dl, Hemoglobin≤100mg/dl, VC≤40mg/dl, NH4+≤1mM, Ca2+≤10mM, Fe3+≤200μM, Mg2+≤10mM, Cu2+≤100μM, Zn2+≤100μM

PRECISION
The CV of the test should be less than 5%.

More Less

Product category: Controls / Standards / Calibrators clinical chemistry

Cystatin C

Method: Immunoturbidimetric

INTENDED USE
The Cystatin C test system is a device intended for the in vitro quantitative determination of Cys C in serum or plasma.

CLINICAL SIGNIFICANCE

Glomerular Filtration Rate (GFR) is a direct marker of renal functions, which starts to decline early in the course of renal diseases. Accurate determination of GFR is required for monitoring the progress of renal diseases when deciding on therapy to avoid impairing the organ function. GFR is determined by measuring the clearance of exogenous substances such as inulin, iohexol and so on, which can freely filter through the glomerular membrane and re-enter the circulation. However, their routine measurement is limited for technical, economical and organizational reasons. Determination of creatinine clearance is the most widely used method for non-invasive estimation of GFR in current practice. Serum creatinine is usually considered moderately specific but of poor sensitivity, as significant increases are only observed if GFR is reduced to 50% or less (creatinine blind range).Creatinine evaluation is influenced by a muscle mass, body surface and flood intake, so it must consider about the age, gender, height and body composition. Creatinine clearance leads to significant overestimation on GFR in case of patients with highly decreased GFR due to tubular secretion. The collection of 24 hr urine is time-consuming and creates additional sources of errors.

Cystatin C is a base proteinase inhibitor with a low molecular mass of 13Kd, and it is produced at a constant rate in all nucleated cells and appears in human plasma and serum. Cystatin C is freely filtered through the glomerulus, is not secreted by the tubule or eliminated via any extra-renal route, and is almost completely absorbed and catabolized by proximal tubular cells.

Cystatin C is not influenced by acute phase reaction (vs. Beta2-microgloblin), and not influenced by endogenous or analytical factor (vs. creatinine or creatinine clearance). These advantages makes Cystatin C an excellent non-invasive indicator for GFR.

Clinical applications of Cystatin C are for monitoring GFR in children and elderly patients, for assessment of renal transplantation status, for monitoring GFR in nephrotoxic drug therapy, for monitoring GFR in acute and chronic kidney diseases including a diabetic nephropathy.
 
ASSAY PRINCIPLE

Sample is reacted with a buffer and anti-Cys C coated latex. The formation of the antibody-antigen complex during the reaction results in an increase in turbidity, the extent of which is measured as the amount of light absorbed at 570 nm. By constructing a standard curve from the absorbance of the standards, Cystatin C concentration of sample can be determined.

 LINEARITY
The method is linear up to a concentration of 0.05-8.0 mg/L. Sample above this concentration should be diluted 1:1 with 0.9% NaCL and repeat assay. Multiply the result by 2.

INTERFERENCE
The following analytes concentrations were not found to affect the assay:
Hemoglobin: up to 500 mg/dl
Bilirubin: up to 20 mg/dl
Introllipid: up to 2500 mg/dl
Ascorbic acid: up to 50 mg/dl

RF: up to 500 IU/ml

SENSITIVITY
The minimum detectable level of Cys C with an acceptable level of precision has been determined as 0.05 mg/L.
 
PRECISION
The CV of the test should be ≤ 5%.

More Less

Product category: Controls / Standards / Calibrators clinical chemistry

CRP (ultra sensitive)

Method: Immunoturbidimetric

 INTENDED USE

For the in vitro quantitative determination of CRP in serum and plasma samples.

 CLINICAL SIGNIFICANCE
CRP (C-reactive protein) is an acute phase protein whose concentration is seen to increase as a result of the inflammatory process, most notably in response to pneumococcal (bacterial) infectious, histolytic disease and a variety of disease states. Originally discovered by Tillet et al. in 1930 in patient sera with acute infection, CRP has now come to be used as a marker or general diagnostic indicator of infections and inflammation, in addition to serving as a monitor of patient response to therapy and surgery. Furthermore, regular measurements of CRP in infants can be a useful aid in the early diagnosis of infectious disease.

 PRINCIPLE
When an antigen-antibody reaction occurs between CRP in a sample and anti-CRP antibody which has been sensitized to latex particles, agglutination results. This agglutination is detected as an absorbance change (572 nm), with the magnitude of the change being proportional to the quantity of CRP in the sample. The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of known concentration.

 LINEARITY
The assay is linear up to an CRP concentration of 0.08-35 mg/dl. If the concentration exceeds the top standard value, further dilute the sample 1+1 with 0.9% NaCl. Multiply the result by 2.

INTERFERENCE 
The following analytes were tested up to the levels indicated and found not to interfere:
Hemoglobin: 500 mg/dl
Conjugated Bilirubin: 30 mg/dl
Intralipid: 4%
Ascorbic Acid: 50 mg/dl
RF: 500 IU/ml

SENSITIVITY
The minimum detectable concentration of CRP with an acceptable level of precision was determined as 0.01 mg/dl.

PROZONE
No prozone Phenomenon occurs when CRP ≤ 60mg/dl.

PRECISION 
The CV of the test should be ≤ 5%.

More Less

Product category: Controls / Standards / Calibrators clinical chemistry

Sodium

Method: Enzymatic Colorimetric

INTENDED USE
For the in vitro quantitative determination of Sodium inserum and plasma.

ASSAY PRINCIPLE
Sodium is determined enzymatically via sodium dependent β-galactosidase activity with ONPG as substrate. The absorbance at 405 nm of the product

O-nitrophenyl is proportional to the sodium concentration.

LINEARITYThis method is linear between sodium concentrations of 70 and 195 mmol/L.

INTERFERENCE
The following analytes were tested up to the levels indicated and found not to interfere:
Introlipid ≤ 1000 mg/dl, Bilirubin ≤ 50 mg/dl, Hemoglobin ≤ 500 mg/dl, Vc ≤ 50 mg/dl, K+ ≤10 mM, Ca2+ ≤ 8 mM, Fe3+ ≤ 200 μM, Mg2+ ≤ 5 mM, Cu2+ ≤ 60 μM, Zn2+ ≤ 80 μM.

SENSITIVITY
The minimum detectable concentration of sodium with an acceptable lever of precision was determined as 15.08 mmol/L.

PRECISION
The CV of the test should be CV < 5%.

More Less

About us

Company details

I am so glad to have this opportunity to let you learn more about Beijing Strong Biotechnologies, Inc (BSBE).

Thanking all the partners worldwide, BSBE has been becoming a leading company in Chinese IVD market, keeping a 30% increase annually in sales and profits. BSBE is expecting to have more chances to cooperate, getting flourish win-win outcome in the future.

 After more than ten years involved in Chinese IVD market, BSBE has become a prominent clinical chemistry liquid reagents manufacturerin China. Owing to its excellent performance, BSBE has been consecutively ranked among Forbes “China Best Small & Medium-Sized Enterprises” since 2005.

 BSBE is looking forward to developing partnership globally and hoping to make greater contributions to better healthcare of mankind. Warmly welcome all friends from every corner of the world to visit BSBE!  

More Less